Drugs / GSK2838232
GSK2838232
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03234036 | Aug → Nov 2017 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02795754 | Mar → Dec 2016 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02289495 | Nov 2014 → Jun 2015 | HIV infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02289482 | Nov 2014 → Mar 2015 | HIV infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01802918 | Feb → Nov 2013 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03045861 | Mar 2017 → Apr 2018 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2838232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01802918 ↗ |
| Known as | GSK2838232 IR1 | “Drug: GSK2838232 IR1” NCT02795754 ↗ |
| Known as | GSK2838232 IR2 | “Drug: GSK2838232 IR2” NCT02795754 ↗ |
| Known as | GSK2838232 PIB | “Drug: GSK2838232 PIB” NCT02795754 ↗ |
| Modality | Small molecule | — CHEMBL4303141 ↗ |
| Route | Oral | “Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily” NCT01802918 ↗ |